Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Bone Metastasis-Pipeline Review, H1 2015

Bone Metastasis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Bone Metastasis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Bone Metastasis-Pipeline Review, H1 2015', provides an overview of the Bone Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Bone Metastasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bone Metastasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bone Metastasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Bone Metastasis Overview 9

Therapeutics Development 10

Pipeline Products for Bone Metastasis-Overview 10

Pipeline Products for Bone Metastasis-Comparative Analysis 11

Bone Metastasis-Therapeutics under Development by Companies 12

Bone Metastasis-Therapeutics under Investigation by Universities/Institutes 14

Bone Metastasis-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Bone Metastasis-Products under Development by Companies 18

Bone Metastasis-Products under Investigation by Universities/Institutes 20

Bone Metastasis-Companies Involved in Therapeutics Development 21

Ablynx NV 21

Alethia Biotherapeutics Inc. 22

Amgen Inc. 23

Amura Holdings Ltd. 24

Bayer AG 25

ChemoCentryx, Inc. 26

Debiopharm International S.A. 27

Deciphera Pharmaceuticals, LLC 28

Digna Biotech, S.L. 29

Medivir AB 30

Merrion Pharmaceuticals Plc 31

Osteologix Holdings Plc. 32

R-Pharm 33

Sigma-Tau S.p.A. 34

Bone Metastasis-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Combination Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

AB-25E9-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ADM-01-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

alendronate sodium + HPMA + paclitaxel-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

alendronate sodium + paclitaxel + PEG-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ALX-0141-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

AM-3701-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AMG-161-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

CCX-721-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

DCC-2909-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

DCC-3014-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Debio-0719-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

denosumab-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

disitertide-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Drugs to Inhibit EGFR for Bone Metastasis-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

MIV-710-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

MIV-711-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

NBS-101-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

P-17-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

radium Ra 223 dichloride-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

RPH-203-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

SST-0001-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

TPH-9-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Vicrostatin-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

zoledronic acid-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Bone Metastasis-Recent Pipeline Updates 79

Bone Metastasis-Dormant Projects 95

Bone Metastasis-Discontinued Products 97

Bone Metastasis-Product Development Milestones 98

Featured News & Press Releases 98

May 23, 2014: Daiichi Sankyo Receives Approval in Japan for Additional Indication Related to RANMARK for Treatment of Giant Cell Tumor of Bone 98

Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders 98

Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics 99

Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo 100

Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 101

May 30, 2013: Algeta Announces First Sale Of Xofigo In US 102

Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 103

Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride 104

Oct 23, 2012: Amgen's Xgeva Obtains Approval From NICE For Eligibility To NHS Funding 104

Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress 105

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

List of Tables

Number of Products under Development for Bone Metastasis, H1 2015 10

Number of Products under Development for Bone Metastasis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Bone Metastasis-Pipeline by Ablynx NV, H1 2015 21

Bone Metastasis-Pipeline by Alethia Biotherapeutics Inc., H1 2015 22

Bone Metastasis-Pipeline by Amgen Inc., H1 2015 23

Bone Metastasis-Pipeline by Amura Holdings Ltd., H1 2015 24

Bone Metastasis-Pipeline by Bayer AG, H1 2015 25

Bone Metastasis-Pipeline by ChemoCentryx, Inc., H1 2015 26

Bone Metastasis-Pipeline by Debiopharm International S.A., H1 2015 27

Bone Metastasis-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 28

Bone Metastasis-Pipeline by Digna Biotech, S.L., H1 2015 29

Bone Metastasis-Pipeline by Medivir AB, H1 2015 30

Bone Metastasis-Pipeline by Merrion Pharmaceuticals Plc, H1 2015 31

Bone Metastasis-Pipeline by Osteologix Holdings Plc., H1 2015 32

Bone Metastasis-Pipeline by R-Pharm, H1 2015 33

Bone Metastasis-Pipeline by Sigma-Tau S.p.A., H1 2015 34

Assessment by Monotherapy Products, H1 2015 35

Assessment by Combination Products, H1 2015 36

Number of Products by Stage and Target, H1 2015 38

Number of Products by Stage and Mechanism of Action, H1 2015 40

Number of Products by Stage and Route of Administration, H1 2015 42

Number of Products by Stage and Molecule Type, H1 2015 44

Bone Metastasis Therapeutics-Recent Pipeline Updates, H1 2015 79

Bone Metastasis-Dormant Projects, H1 2015 95

Bone Metastasis-Dormant Projects (Contd..1), H1 2015 96

Bone Metastasis-Discontinued Products, H1 2015 97

List of Figures

Number of Products under Development for Bone Metastasis, H1 2015 10

Number of Products under Development for Bone Metastasis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Top 10 Targets, H1 2015 37

Number of Products by Stage and Top 10 Targets, H1 2015 37

Number of Products by Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Top 10 Routes of Administration, H1 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 43

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ablynx NV

Alethia Biotherapeutics Inc.

Amgen Inc.

Amura Holdings Ltd.

Bayer AG

ChemoCentryx, Inc.

Debiopharm International S.A.

Deciphera Pharmaceuticals, LLC

Digna Biotech, S.L.

Medivir AB

Merrion Pharmaceuticals Plc

Osteologix Holdings Plc.

R-Pharm

Sigma-Tau S.p.A.

Bone Metastasis Therapeutic Products under Development, Key Players in Bone Metastasis Therapeutics, Bone Metastasis Pipeline Overview, Bone Metastasis Pipeline, Bone Metastasis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com